{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:11:21Z","timestamp":1785337881198,"version":"3.55.0"},"reference-count":15,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Robert Wood Johnson Foundation","award":["1K01NS126736-01"],"award-info":[{"award-number":["1K01NS126736-01"]}]},{"name":"Harold Amos Faculty Development Award","award":["1K01NS126736-01"],"award-info":[{"award-number":["1K01NS126736-01"]}]},{"name":"NIH-NINDS","award":["1K01NS126736-01"],"award-info":[{"award-number":["1K01NS126736-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Cannabidiol (CBD) is a non-intoxicating chemical in cannabis plants that is being investigated as a candidate for treatment in Fragile X Syndrome (FXS), a leading known cause of inherited intellectual developmental disability. Studies have shown that CBD can reduce symptoms such as anxiety, social avoidance, hyperactivity, aggression, and sleep problems. This is a qualitative study that utilized a voluntary-anonymous survey that consisted of questions regarding demographics, medical information, the form, type, brand, dose, and frequency of CBD use, the rationale for use, the perception of effects, side effects, and costs. The full survey contained a total of 34 questions, including multiple-choice, Likert-scale, and optional free-response questions. This research revealed that there are a wide range of types, brands, and doses of CBD being administered to individuals with FXS by their parents and caregivers. There were many reasons why CBD was chosen, the most common ones being that respondents had heard positive things about CBD from members of the community, the perception that CBD had fewer side effects than other medications, and because respondents felt that CBD was a more natural substance. Most of the parents and caregivers who responded agreed that CBD improved some of the symptoms of FXS and made a positive difference overall. CBD has the therapeutic potential to help relieve some FXS symptoms. Future research is necessary to understand the benefits of CBD in FXS.<\/jats:p>","DOI":"10.3390\/genes13091594","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T20:52:51Z","timestamp":1662497571000},"page":"1594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Parent and Caregiver Perspectives towards Cannabidiol as a Treatment for Fragile X Syndrome"],"prefix":"10.3390","volume":"13","author":[{"given":"Madison","family":"Maertens","sequence":"first","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Silver","sequence":"additional","affiliation":[{"name":"Department of Counseling and Clinical Psychology, Teachers College, Columbia University, New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Dixon Weber","sequence":"additional","affiliation":[{"name":"National Fragile X Foundation, McLean, VA 22102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Rosselot","sequence":"additional","affiliation":[{"name":"National Fragile X Foundation, McLean, VA 22102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-5854","authenticated-orcid":false,"given":"Reymundo","family":"Lozano","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"National Fragile X Foundation, McLean, VA 22102, USA"},{"name":"Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.25100\/cm.v45i4.1810","article-title":"Fragile X syndrome","volume":"45","author":"Saldarriaga","year":"2014","journal-title":"Colomb. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5582\/irdr.2014.01022","article-title":"Fragile X spectrum disorders","volume":"3","author":"Lozano","year":"2014","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pbb.2019.05.002","article-title":"Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism","volume":"181","author":"Zieba","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The Endocannabinoid System as an Emerging Target of Pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ncomms2045","article-title":"Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome","volume":"3","author":"Jung","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1476-5381.2010.01063.x","article-title":"Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action","volume":"162","author":"Maione","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.2174\/1381612821666150914121038","article-title":"Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder","volume":"21","author":"Lozano","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/can.2018.0053","article-title":"Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature","volume":"4","author":"Tartaglia","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J. Neurodev. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/1573396315666190625110748","article-title":"New Targeted Treatments for Fragile X Syndrome","volume":"15","author":"Protic","year":"2019","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/9\/1594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:24:08Z","timestamp":1760142248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/9\/1594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["genes13091594"],"URL":"https:\/\/doi.org\/10.3390\/genes13091594","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]}}}